BIOMAT Database Logo BIOMAT Database Logo

Production and characterization of human monoclonal antibody recognizing the N-terminal residues of Pseudomonas aeruginosa exotoxin A. 1991

H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Laboratory of Biotechnology, Takarazuka Research Center, Sumitomo Chemical Co., Ltd., Hyogo, Japan.

Human cell lines producing monoclonal antibodies (MAbs) against Pseudomonas aeruginosa exotoxin A were established by EBV transformation followed by cell fusion. Monoclonal antibody FK-001, IgM (mu, kappa), was demonstrated to be specifically reactive with exotoxin A in ELISA and immunoblotting, by recognizing N-terminal 16 amino acid residues of exotoxin A as an epitope. This epitope region belongs to domain I which is required for the binding of exotoxin A to the receptor on target cells. FK-001 showed a partial neutralizing activity for cell toxicity caused by exotoxin A and appeared to be effective against exotoxin A-producing P. aeruginosa infection in mice. A line of evidence suggests that monoclonal antibody FK-001 neutralizes exotoxin A-induced cell toxicity by the interference of accessibility and/or binding of exotoxin A to animal cell receptors.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002459 Cell Fusion Fusion of somatic cells in vitro or in vivo, which results in somatic cell hybridization. Cell Fusions,Fusion, Cell,Fusions, Cell
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D004854 Herpesvirus 4, Human The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies. Burkitt Herpesvirus,Burkitt Lymphoma Virus,E-B Virus,EBV,Epstein-Barr Virus,Human Herpesvirus 4,Infectious Mononucleosis Virus,Burkitt's Lymphoma Virus,HHV-4,Herpesvirus 4 (gamma), Human,Burkitts Lymphoma Virus,E B Virus,E-B Viruses,Epstein Barr Virus,Herpesvirus, Burkitt,Infectious Mononucleosis Viruses,Lymphoma Virus, Burkitt,Mononucleosis Virus, Infectious,Mononucleosis Viruses, Infectious
D005098 Exotoxins Toxins produced, especially by bacterial or fungal cells, and released into the culture medium or environment. Exotoxin

Related Publications

H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa.
May 1984, Infection and immunity,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A.
November 1996, Clinical and diagnostic laboratory immunology,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
[Production and properties evaluation of monoclonal antibodies against Pseudomonas aeruginosa exotoxin A].
January 2014, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
A human-human hybridoma secreting anti-Pseudomonas aeruginosa exotoxin-A monoclonal antibody with highly potent neutralizing activity.
January 1990, Cytotechnology,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Characterization of exotoxin of Pseudomonas aeruginosa.
November 1974, The Journal of infectious diseases,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Purification and characterization of Pseudomonas aeruginosa exotoxin.
January 1974, Infection and immunity,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Pseudomonas aeruginosa exotoxin A.
January 1992, Targeted diagnosis and therapy,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Pseudomonas aeruginosa exotoxin A.
June 1980, The New England journal of medicine,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Therapy of human cervical carcinoma with monoclonal antibody-Pseudomonas exotoxin conjugates.
August 1991, Cancer research,
H Ohtsuka, and K Horigome, and H Ochi, and T Nishimoto, and T Kozuki, and M Kato, and T Okuda, and H Noguchi
Exotoxin production by clinical isolates of pseudomonas aeruginosa.
March 1977, Infection and immunity,
Copied contents to your clipboard!